COVID-19 has created havoc in the world by causing thousands of demises in a short period of time. Up till now, several attempts have been made for potential therapeutics against SARS-COV2. In this retrospective, single-center study, we extracted data from 122 COVID-19, RT-PCR confirmed patients. who were treated with a new treatment strategy of lianhuaqingwen with Arbidol Hydrochloride. The patients were either asymptomatic or had mild symptoms for COVID-19 disease. Of 122 patients 21 (17.21%) patients developed severe conditions of COVID-19, while total 111 (90.9%) experienced mild symptoms such as fever in 93 (76.22%) patients, cough in 23 (20.17%) and muscle pain were observed in total 8 (7%) patients. Furthermore our newly applied drugs combination (Lianhuaqingwen and Arbidol Hydrochloride) showed therapeutic effects in 5–7 days in patients with mild symptoms with 98% recovery rate. These results indicate that COVID-19 patients with mild symptoms can be treated with Lianhuaqingwen and Arbidol Hydrochloride. However, extensive clinical investigations are required to confirm the effectiveness of these drugs.

COVID-19 在短时间内造成了数千人死亡，给世界造成了严重破坏。到目前为止，已经针对 SARS-COV2 的潜在治疗方法进行了多次尝试。在这项回顾性单中心研究中，我们从 122 名经 RT-PCR 确诊的 COVID-19 患者中提取了数据。接受连花清瘟联合盐酸阿比朵尔新治疗策略的患者。这些患者要么没有症状，要么有轻微的 COVID-19 症状。在 122 名患者中，21 名（17.21%）名患者出现严重的 COVID-19 症状，共有 111 名（90.9%）名患者出现轻微症状，其中 93 名（76.22%）名患者出现发烧，23 名（20.17%）名患者出现咳嗽，并观察到肌肉疼痛总共 8 名（7%）患者。此外，我们新应用的药物组合（连花清瘟和盐酸阿比朵尔）对症状较轻的患者在5-7天内显示出疗效，治愈率高达98%。这些结果表明，症状较轻的COVID-19患者可以使用连花清瘟和盐酸阿比朵尔治疗。然而，需要广泛的临床研究来证实这些药物的有效性。